Cholera Vaccines Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 102.89 Million |
| Market Size (2030) | USD 170.94 Million |
| Growth Rate (2025 - 2030) | 10.69% CAGR |
| Fastest Growing Market | North America |
| Largest Market | Asia Pacific |
| Market Concentration | High |
Major Players*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Cholera Vaccines Market Analysis by Mordor Intelligence
The cholera vaccines market stood at USD 102.89 million in 2025 and is forecast to reach USD 170.94 million by 2030, advancing at a 10.69% CAGR. This outlook reflects a hard pivot from reactive outbreak control toward systematic, preventive immunization programs as global transmission accelerates. Demand is intensifying in Asia-Pacific, where India, China, and several Southeast Asian nations are scaling seasonal campaigns in response to climate-related flooding and rising sea-surface temperatures. Supply-side momentum is equally strong: EuBiologics’ simplified killed-vaccine formulation and Gavi’s USD 1.2 billion African Vaccine Manufacturing Accelerator are expanding capacity while de-risking geographic concentration. At the same time, single-dose live vaccines and mRNA platforms promise faster protection and rapid strain adaptation, creating new commercial niches in travel medicine and emergency response. Together, these factors keep the cholera vaccines market on a steep growth trajectory despite periodic stockpile shortfalls.
Key Report Takeaways
- By vaccine type, Killed Oral O1 and O139 formulations led with 74.54% of cholera vaccines market share in 2024; Whole cell V. cholerae O1 plus recombinant B-subunit vaccines are expanding at an 11.34% CAGR through 2030.
- By product, Dukoral accounted for 38.98% of revenue in 2024, while Vaxchora is projected to rise at an 11.29% CAGR to 2030.
- By distribution channel, public sector procurement held 71.77% of the cholera vaccines market size in 2024; private-channel sales are accelerating at 11.56% CAGR on the back of travel-clinic demand.
- By region, Asia-Pacific is the fastest-growing geography at 11.89% CAGR, whereas North America retained the largest revenue share at 37.67% in 2024.
Global Cholera Vaccines Market Trends and Insights
Drivers Impact Analysis
| Driver | ( ~ ) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Escalating multi-continent outbreaks | +2.1% | Africa, Asia-Pacific | Short term (≤ 2 years) |
| Expanded Gavi OCV stockpile funding | +1.8% | Low- and middle-income countries | Medium term (2-4 years) |
| Climate-linked coastal flooding | +1.5% | Asia-Pacific, Sub-Saharan Africa | Long term (≥ 4 years) |
| Live single-dose approvals in travel clinics | +1.2% | North America, Europe | Medium term (2-4 years) |
| mRNA rapid-switch platforms | +0.9% | High-income markets | Long term (≥ 4 years) |
| OCV inclusion in WHO rapid-response kits | +0.8% | Conflict zones | Short term (≤ 2 years) |
Source: Mordor Intelligence
Escalating Multi-Continent Outbreaks
Thirty-three countries reported active cholera outbreaks in December 2024, more than double the historical norm, underscoring shifting epidemiology driven by extreme weather and population displacement [1]World Health Organization, "Multi-country cholera outbreak, external situation report," who.int. Rising case-fatality ratios in fragile health systems are propelling governments toward pre-emptive vaccination rather than purely reactive campaigns, thereby lifting baseline demand across the cholera vaccines market. Expanded geographic spread into previously cholera-free zones further stretches stockpile requirements, increasing order volumes and sustaining commercial growth. Health agencies are now forecasting vaccine needs on a multi-year basis, giving manufacturers stronger demand visibility that underpins capacity investments. Elevated outbreak frequency therefore exerts the single largest positive influence on the market outlook.
Expanded Gavi OCV Stockpile Funding
Gavi’s pledge to supply 230 million doses to 31 countries—and its record 96 million-dose shipment over the past two years—marks the largest coordinated cholera vaccination effort to date. The African Vaccine Manufacturing Accelerator allocates USD 1.2 billion to regional production, with France contributing EUR 10 million, signaling long-term procurement security for producers [2]Gavi, " Protecting more children, against more diseases, faster than ever before: Gavi, the Vaccine Alliance unveils plans for next 5-year period, " gavi.org. Preventive campaigns need three to four times more doses than reactive drives, directly scaling the cholera vaccines market. Guaranteed offtake contracts de-risk capital spending, accelerate line expansions, and encourage technology transfer to Africa and Asia, ultimately broadening supply resilience. Together these funding mechanisms inject consistent volume growth into the forecast period.
Climate-Linked Coastal Flooding in Endemic Megacities
Meteorological data connect heavier rainfall, warmer seas, and inadequate sanitation to Vibrio cholerae proliferation in coastal megacities. [3]Center for Disease Control and Prevention, "A summary of health effects, resources, and adaptation examples from health departments funded by CDC’s Climate and Health Program," cdc.gov Flood events precede cholera spikes by 2-3 weeks, providing a predictive window for vaccination. Urban centers with more than 5 million inhabitants face compounding climate and infrastructure risk, prompting ministries of health to budget seasonal vaccine buys. This driver sustains double-digit demand growth in Asia-Pacific and Sub-Saharan Africa across the forecast horizon.
Live Single-Dose Approvals in Travel Clinics
The FDA-approved live oral vaccine Vaxchora shows 90.3% efficacy after 10 days, eliminating the compliance gap inherent in two-dose regimens. Travel clinics favor the convenience of single-visit dosing, and insurers in North America and Europe reimburse the premium, creating a lucrative private-sector niche within the cholera vaccines market. Strong traveler uptake has triggered additional regulatory filings in Europe and Asia, broadening revenue streams that are independent of humanitarian cycles.
Restraints Impact Analysis
| Restraint | ( ~ ) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Two-dose compliance gaps | −1.4% | Mobile and refugee populations | Short term (≤ 2 years) |
| OMV component bottlenecks | −1.1% | Asia-centric supply chain | Medium term (2-4 years) |
| Low incentives in non-endemic high-income markets | −0.8% | North America, Europe | Long term (≥ 4 years) |
| Hybrid O139-O1 strain drift | −0.6% | Asia-Pacific | Medium term (2-4 years) |
Source: Mordor Intelligence
Two-Dose Compliance Gaps
Second-dose completion rates dip to 64-73% in mass campaigns, limiting population immunity and prompting calls for simpler schedules. Barriers include migration, competing livelihoods, and inadequate community messaging. Although alternative delivery models—such as self-administration or extended intervals—improve uptake, each adds logistical complexity. The constraint reduces effective coverage and tempers near-term growth projections, catalyzing investment in single-dose approaches that can close the compliance gap.
OMV Component Bottlenecks
Outer membrane vesicle-based candidates promise broader antigenic coverage but require specialized processing to control endotoxicity, and global capacity is concentrated among a handful of Asian suppliers. Any production hiccup reverberates through the entire cholera vaccines market, as seen in the 2024 stock-out. Capital-heavy upgrades and stringent quality checks lengthen scale-up timelines, restraining supply even as demand climbs.
Segment Analysis
By Vaccine Type: Killed Vaccines Maintain Dominance Amid Innovation
Killed Oral O1 and O139 vaccines generated 74.54% of the cholera vaccines market in 2024, a position secured by decades of field evidence and WHO prequalification. The segment accounted for the largest cholera vaccines market size portion at USD 77 million in 2025. Capacity gains from EuBiologics’ Euvichol-S line alone will add 50 million doses annually, strengthening supply resilience. However, recombinant B-subunit enhancements are unlocking higher pediatric efficacy and, at 11.34% CAGR, are the fastest-advancing sub-segment through 2030.
Live-attenuated candidates, though still niche, match the industry’s pivot toward single-dose ease. Vaxchora exemplifies the commercial potential: its 90.3% short-term efficacy and 79.5% at three months position it as the traveler’s vaccine of choice. Development pipelines include edible rice-based formulations and mRNA prototypes that could bypass cold chains, underscoring an innovation race likely to re-shape competitive dynamics after 2027.
By Product: Dukoral’s Legacy vs. Vaxchora’s Momentum
Dukoral held 38.98% of revenue in 2024, buoyed by long-standing WHO approval and entrenched travel-clinic usage. Yet Vaxchora is set to outpace every other brand at 11.29% CAGR through 2030, carving a profitable lane in single-dose convenience.
Public-sector stalwarts Euvichol-Plus and Shanchol continue to dominate humanitarian procurement on price, reinforcing their role in large-scale preventive programs funded by Gavi. The “Others” category—housing regional candidates and pipeline products—could disrupt share splits once late-stage trials read out post-2027.
By Distribution Channel: Private Sector Acceleration
Public tenders still delivered 71.77% of the cholera vaccines market size in 2024, underpinned by UNICEF and Gavi contracts that absorb volume at cost-plus pricing. Private sales, though smaller, are expanding at 11.56% CAGR, led by travel-clinic chains and corporate occupational-health programs in North America and Europe.
The dual-channel structure enables cross-subsidization: higher private-sector prices offset low margins in humanitarian supply, supporting manufacturer profitability and R&D spend.
Geography Analysis
North America commanded 37.67% of 2024 revenue, propelled by Vaxchora’s premium pricing and a mature travel-health infrastructure that guarantees consistent uptake even during global shortages. Corporate duty-of-care policies further institutionalize demand, ensuring that private-sector volumes remain insulated from humanitarian stockpile dynamics.
Asia-Pacific is the fastest-growing territory, advancing at an 11.89% CAGR through 2030 as India, Bangladesh, and Vietnam shift to routine pre-monsoon vaccination. National demonstration projects have validated cost-effectiveness, attracting multilateral financing that secures multiyear procurement. Emerging manufacturing hubs in India will shorten supply chains and curb freight costs, reinforcing regional self-sufficiency.
Europe maintains a dual role as both buyer and manufacturer. Robust regulatory frameworks, coupled with Sanofi’s EUR 1 billion investment in flexible bioproduction, support future mRNA-based cholera candidates. Meanwhile, development assistance from France and the EU is channeling technology transfer to Africa, reflecting a policy stance that sees vaccine self-reliance as a pillar of global health security.
Competitive Landscape
The cholera vaccines market is concentrated. EuBiologics’ rapid scale-up after WHO prequalification highlights first-mover advantage in streamlined killed-vaccine manufacturing, but the 2024 stock-out also exposed systemic risk. Gavi’s African accelerator aims to widen the producer base by 2027 through technology licenses and subsidized capex, directly challenging single-supplier dominance.
Innovation competition is heating up. Valneva is advancing a recombinant B-subunit candidate with Phase 3 readouts expected in 2026, while Emergent BioSolutions is piloting modular plant designs for OMV products. Sanofi’s new French facility includes dedicated mRNA capacity adaptable to bacterial targets, positioning the firm for potential platform leadership. Investors are rewarding companies that can flex production in emergencies, shifting the competitive narrative from brand loyalty to supply dependability.
Strategic partnerships are multiplying: EuBiologics has signed fill-finish agreements in India, Valneva is collaborating with the Coalition for Epidemic Preparedness Innovations on antigen-switch platforms, and African Union health agencies are negotiating offtake guarantees conditional on local manufacturing. These moves are likely to re-balance market shares and dilute concentration by the latter half of the decade.
Cholera Vaccines Industry Leaders
-
Sanofi
-
GlaxoSmithKline LLC
-
Astellas Pharma Inc
-
Pfizer Inc.
-
Merck & Co. Inc.
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- June 2025: WHO launched a 2.6 million-person oral cholera vaccination campaign in conflict-affected Khartoum State, Sudan, marking the largest immunization drive ever conducted in an active war zone.
- June 2024: Gavi unveiled the USD 1.2 billion African Vaccine Manufacturing Accelerator, earmarking funds for regional cholera vaccine production and receiving a EUR 10 million contribution from France.
- April 2024: WHO prequalified Euvichol-S, a simplified killed vaccine that can boost annual output by 50 million doses, easing global shortages.
- April 2024: WHO distributed 1.2 million cholera rapid diagnostic tests to 14 countries, accelerating case confirmation and vaccination deployment.
Global Cholera Vaccines Market Report Scope
As per the scope of the report, cholera is caused by Vibrio cholerae via the consumption of contaminated food or water. The infected individuals suffer from severe watery diarrhea, eventually leading to dehydration, which, if unattended, may lead to death owing to access water loss. Oral vaccination has been observed to be the best preventive treatment for cholera and has proved to be very useful in preventing huge outbreaks.
The Cholera Vaccines Market is segmented by Vaccine Type (Whole cell V. cholerae O1 with Recombinant B-subunit, Killed Oral O1, and O139), Product (Vaxchora, Dukoral, Shanchol, and Other Products), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Vaccine Type | Whole cell V. cholerae O1 with Recombinant B-subunit | ||
| Killed Oral O1 and O139 | |||
| By Product | Dukoral | ||
| Euvichol-Plus | |||
| Vaxchora | |||
| Others | |||
| By Distribution Channel | Public | ||
| Private | |||
| By Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Whole cell V. cholerae O1 with Recombinant B-subunit |
| Killed Oral O1 and O139 |
| Dukoral |
| Euvichol-Plus |
| Vaxchora |
| Others |
| Public |
| Private |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Key Questions Answered in the Report
What is the current size of the cholera vaccines market?
The cholera vaccines market reached USD 102.89 million in 2025 and is projected to attain USD 170.94 million by 2030.
Which region is expanding the fastest?
Asia-Pacific leads growth at an 11.89% CAGR, driven by large-scale preventive campaigns in India, China, and Southeast Asia.
Why are single-dose vaccines gaining traction?
Single-dose live vaccines such as Vaxchora remove the second-dose compliance barrier and deliver protection within 10 days, making them attractive for travelers and outbreak emergencies.
How is Gavi influencing supply dynamics?
Gavi’s procurement guarantees and its USD 1.2 billion African manufacturing initiative provide long-term demand visibility and encourage new regional production capacity.
What manufacturing risks threaten supply?
Supply remains vulnerable to outer membrane vesicle production bottlenecks and heavy reliance on a few Asian suppliers, though technology transfer programs aim to diversify capacity by 2027.
What role could mRNA platforms play?
MRNA technology promises faster antigen updates and scalable output, potentially shortening development cycles from years to months and improving responsiveness to emerging cholera strains.
Page last updated on: June 30, 2025
